Bluebird bio Inc (NASDAQ: BLUE) Seen Running Too Hot, Let’s Look At This More Closely

Currently, there are 192.74M common shares owned by the public and among those 187.59M shares have been available to trade.

Insiders at the company have transacted a total of 15 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 10 of these insider trades were purchases, accounting for 247,003 shares. Insider sales of the common stock occurred on 5 occasions, with total insider shares sold totaling 25,131 shares.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The company’s stock has a 5-day price change of 20.42% and -64.09% over the past three months. BLUE shares are trading -21.01% year to date (YTD), with the 12-month market performance down to -82.07% lower. It has a 12-month low price of $0.88 and touched a high of $6.07 over the same period. BLUE has an average intraday trading volume of 0.49 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.01%, -44.30%, and -64.97% respectively.

Institutional ownership of Bluebird bio Inc (NASDAQ: BLUE) shares accounts for 54.33% of the company’s 192.74M shares outstanding.

It has a market capitalization of $210.09M and a beta (3y monthly) value of 0.68. The earnings-per-share (ttm) stands at -$0.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.17% over the week and 8.74% over the month.

Analysts forecast that Bluebird bio Inc (BLUE) will achieve an EPS of -$0.66 for the current quarter, -$0.5 for the next quarter and -$1.77 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.98 while analysts give the company a high EPS estimate of -$0.38. Comparatively, EPS for the current quarter was $0.38 a year ago. Earnings per share for the fiscal year are expected to increase by 44.03%, and 10.49% over the next financial year. EPS should grow at an annualized rate of 45.80% over the next five years, compared to 15.14% over the past 5-year period.

Most Popular

Related Posts